Pacific Biosciences of California, Inc. (PACB) or PacBio recently announced a collaboration with HiFi Solves Sub-Fertility Consortium, led by KK Women's and Children's Hospital in Singapore. The consortium will use PACB's HiFi long-read sequencing to pioneer advancements in diagnosing and treating subfertility and recurrent pregnancy loss (RPL). The consortium includes experts from five leading centers across the AsiaPacific region and leverages DNAstack's federated data platform to ensure secure, global co ...

Pacific Biosciences of California, Inc. (PACB) has announced a collaboration with the University Hospital of Munster to use its Revio HiFi sequencing system in advancing research on male infertility and rare diseases. Munster is pioneering long-read whole genome sequencing in Germany, integrating it into research and diagnostics. This initiative will explore complex genetic issues, including the Y chromosome's role in male infertility, and support Germany's GenomeDE Modellvorhaben project. The results will ...

SINGAPORE, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The HiFi Solves Sub-fertility Consortium, an innovative collaboration involving five leading centers across the Asia-Pacific region, announces work aimed at redefining the landscape of fertility research. Utilizing PacBio HiFi long-read sequencing, the consortium, led by KK Women's and Children's Hospital (KKH) in Singapore, is pioneering the use of PacBio HiFi long-read sequencing to enhance the diagnosis and treatment of subfertility and recurrent miscarriages ...

MENLO PARK, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a collaboration with the University Hospital of Münster, to use long-read whole genome sequencing to significantly advance male infertility and rare disease research. By deploying PacBio's Revio HiFi sequencing system, researchers at Münster will obtain highly accurate genomic data essential for addressing complex genetic issues associated w ...

Mongkol Onnuan Pacific Biosciences: Sustained Weakness in Genomic Sequencing Market Pacific Biosciences of California's (NASDAQ:PACB) stock is down 20% since my "sell" recommendation in June following its Q1 earnings report. I expressed concerns regarding Pacific's "high SG&A costs (relative to revenues), declining product revenues, and low gross margins" amidst a competitive genomic sequencing market. The company reported Q2 earnings on August 7. Unfortunately, the results continue to highlight the signifi ...

alanphillips/E+ via Getty Images The performance of Pacific Biosciences (NASDAQ:PACB) ("PacBio") is all too familiar to readers who've followed this stock for a long time, as once again the stock is trading below $2 on fears that the company simply won't be able to stay in the game long enough to benefit from future growth in long-read sequencing (as well as skepticism that long-read sequencing will grow enough to support a $1B+ revenue base). Down more than 80% since my last update, underperforming other s ...

Pacific Biosciences of California (PACB) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following ...

Table of Contents UNITED STATES (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 | --- | --- | |------------------------|----------------------------------------------------------------------------------------------------------------------------------| | Washington, D.C. 20549 | SECURITIES AND EXCHANGE COMMISSION _____________________________________________________________________________________________ | | Fo ...

Core Viewpoint - Pacific Biosciences of California, Inc. (PacBio) reported mixed results for the second quarter of 2024, with adjusted loss per share beating estimates while revenues fell short of expectations [11]. Revenue Analysis - PacBio generated revenues of $36 million in Q2 2024, a decrease of 24.3% year over year, missing the Zacks Consensus Estimate by 11.2% [2]. - Revenue breakdown by region showed: - Americas: $20.8 million, down 13% year over year [3]. - Asia-Pacific: $8.2 million, down 36% year over year [3]. - EMEA: $7 million, down 35% year over year [3]. Segmental Performance - Product revenues were $31.7 million, down 27.3% from the previous year [4]. - Instrument revenues fell to $14.7 million, a 51% decline year over year due to lower Revio unit shipments [4]. - Consumables revenues increased to $17 million, up 24% from the prior year [4]. - Service and other revenues totaled $4.3 million, reflecting a 9% year-over-year increase [5]. Margin and Expense Trends - Adjusted gross profit decreased by 15.9% to $13.2 million, but adjusted gross margin improved by 400 basis points to 37% year over year [6]. - Sales, general and administrative expenses rose by 13.1% to $45.9 million [6]. - Research and development expenses decreased by 16.7% to $38.5 million [6]. - Total operating loss was $175.8 million, wider than the loss of $73.2 million in the prior year [7]. Financial Position - As of the end of Q2 2024, PacBio had cash, cash equivalents, and investments totaling $509.8 million, down from $561.9 million at the end of Q1 2024 [8]. Guidance - PacBio updated its revenue outlook for 2024, expecting revenues to be around the lower end of the $170-$200 million range, with the Zacks Consensus Estimate at $177.5 million [10]. - The company anticipates $80 million in instrument revenues for fiscal 2024, including 115 Revio shipments, and consumable revenues of $72 million [10]. Strategic Developments - In July 2024, PacBio announced a collaboration with Novogene to utilize its Revio long-read sequencing system in a new lab in Munich, Germany [13]. - The company also partnered with Form Bio to advance initiatives in the Adeno-associated virus industry [13]. - In March 2024, PacBio introduced the PureTarget repeat expansion panel, enabling thorough examination of genes linked to severe neurological conditions [14].

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this maker of genetic analysis technology would post a loss of $0.26 per share when it actually produced a loss of $0.26, delivering no surprise. Over the last ...